Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
88
datasets available to search
ShareScore release 0.7.1
Dataset results
88 results for “Personalized medicine”
A personalized medicine approach identifies enasidenib as an efficient treatment for IDH2 mutant chondrosarcoma
GEO Series GSE235701. Homo sapiens. 29 samples. Type: Expression profiling by high throughput sequencing; Methylation profiling by genome tiling array.
A personalized medicine approach identifies enasidenib as an efficient treatment for IDH2 mutant chondrosarcoma [RNAseq_Enasidenib_L2975_SW1353]
GEO Series GSE261434. Homo sapiens. 12 samples. Type: Expression profiling by high throughput sequencing.
Omic Personality: Implications of Stable Transcript and Methylation Profiles for Personalized Medicine
GEO Series GSE67491. Homo sapiens. 101 samples. Type: Expression profiling by high throughput sequencing; Non-coding RNA profiling by high throughput sequencing; Methylation profiling by genome tiling array.
Personalized, Predictive, Precise & Preventive Medicine for Major Depression
ClinicalTrials.gov study NCT06027177. IPD Sharing: YES. Countries: 0. Publications: 0.
Deep sequencing of gastric carcinoma reveals somatic mutations relevant to personalized medicine
GEO Series GSE29999. Homo sapiens. 199 samples. Type: Expression profiling by array; Genome variation profiling by SNP array; SNP genotyping by SNP array.
Identification of clinical trait–related small RNA biomarkers with weighted gene co-expression network analysis for personalized medicine in endocervical adenocarcinoma
GEO Series GSE176579. Homo sapiens. 14 samples. Type: Non-coding RNA profiling by high throughput sequencing.
Can personalized medicine mitigate confirmation bias in mental health?
<p>Can personalized medicine mitigate confirmation bias in<br> mental health? </p> <p> </p>
Personalized medicine in rheumatoid arthritis: How immunogenicity impacts use of TNF inhibitors
<p>Up to 40% of patients treated with tumor necrosis factor alpha inhibitors (TNFi) do not respond to therapy. Testing drug bioavailability and/or anti-drug antibody (ADAb) levels may justify dosage adjustment or switch to different drugs, enabling a personalized medicine approach. We report a multicenter cross-sectional study on different methods [ELISA and a cell based functional assay (reporter gene assay - RGA)] for drug/ADAb detection, and on the relationship between drug bioavailability and ADAb. 163 patients with rheumatoid arthritis (RA) treated with infliximab (IFX; n = 67), adalimumab (ADL; n = 49) or etanercept (ETA; n = 47) were tested for drug and ADAb levels. Furthermore, we report prospective data from additional 70 patients (59 RA and 11 juvenile idiopathic arthritis - JIA) tested for drug and ADAb levels at baseline (T0) and after 3 (T3) and 6 months (T6) of treatment with ADL or ETA only. IFX-treated patients were not included because of the increasing use of IFX biosimilars. Stringent inclusion criteria were used in order to avoid unwanted variables in both studies; none of the patients used TNFi before the study, and TNFi was used only in combination with methotrexate. Clinical response was defined according to EULAR response criteria. The two assays performed comparably in the comparison study. Accordingly, ELISA was selected for the prospective study because of its feasibility in the clinical setting. The cross-sectional study found ADAb in IFX and ADL treated groups only, that were associated with a decrease in pharmacological drug availability in the blood. Comparable results were found for the ADL-treated group in the prospective study which also showed a relationship between drug/ADAb levels and the loss of clinical response. Altogether our findings support drug and anti-drug Ab monitoring in the real-world clinical setting thus enabling individualized treatment and reducing disability in chronic inflammatory arthritis.</p>
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.